Nikulski Financial Inc. Raises Holdings in Eli Lilly and Company (NYSE:LLY)

Nikulski Financial Inc. lifted its stake in Eli Lilly and Company (NYSE:LLY) by 39.7% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 2,869 shares of the company’s stock after purchasing an additional 816 shares during the quarter. Nikulski Financial Inc.’s holdings in Eli Lilly and Company were worth $2,542,000 as of its most recent SEC filing.

A number of other institutional investors also recently bought and sold shares of the stock. HM Payson & Co. raised its stake in Eli Lilly and Company by 1.8% in the 3rd quarter. HM Payson & Co. now owns 21,953 shares of the company’s stock worth $19,449,000 after acquiring an additional 378 shares during the last quarter. Catalyst Financial Partners LLC increased its holdings in shares of Eli Lilly and Company by 3.6% in the third quarter. Catalyst Financial Partners LLC now owns 4,842 shares of the company’s stock valued at $4,290,000 after purchasing an additional 166 shares during the period. Tevis Investment Management raised its stake in shares of Eli Lilly and Company by 3.2% in the third quarter. Tevis Investment Management now owns 925 shares of the company’s stock worth $820,000 after purchasing an additional 29 shares during the last quarter. Goldstone Financial Group LLC acquired a new stake in shares of Eli Lilly and Company during the third quarter worth about $260,000. Finally, Cornerstone Wealth Group LLC boosted its position in Eli Lilly and Company by 2.6% in the third quarter. Cornerstone Wealth Group LLC now owns 12,563 shares of the company’s stock valued at $11,130,000 after buying an additional 324 shares during the last quarter. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on LLY. Citigroup raised their price target on shares of Eli Lilly and Company from $1,060.00 to $1,250.00 and gave the stock a “buy” rating in a research report on Friday, October 25th. Bank of America decreased their target price on shares of Eli Lilly and Company from $1,150.00 to $1,100.00 and set a “buy” rating for the company in a research report on Thursday. Guggenheim upped their price target on shares of Eli Lilly and Company from $884.00 to $1,030.00 and gave the company a “buy” rating in a report on Friday, August 16th. Cantor Fitzgerald reiterated an “overweight” rating and set a $885.00 price objective on shares of Eli Lilly and Company in a research note on Monday, September 16th. Finally, Sanford C. Bernstein assumed coverage on Eli Lilly and Company in a research note on Thursday, October 17th. They issued an “outperform” rating and a $1,100.00 target price on the stock. Three research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $1,009.00.

Eli Lilly and Company Trading Down 2.0 %

Shares of Eli Lilly and Company stock opened at $829.84 on Friday. The company has a current ratio of 1.11, a quick ratio of 0.87 and a debt-to-equity ratio of 1.74. Eli Lilly and Company has a twelve month low of $547.61 and a twelve month high of $972.53. The firm has a market capitalization of $788.70 billion, a PE ratio of 89.71, a P/E/G ratio of 3.07 and a beta of 0.42. The firm’s 50-day moving average price is $913.71 and its 200 day moving average price is $864.86.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Wednesday, October 30th. The company reported $1.18 EPS for the quarter, missing the consensus estimate of $1.52 by ($0.34). Eli Lilly and Company had a return on equity of 73.73% and a net margin of 20.48%. The firm had revenue of $11.44 billion for the quarter, compared to analysts’ expectations of $12.09 billion. During the same quarter in the previous year, the firm posted $0.10 earnings per share. The firm’s revenue for the quarter was up 20.4% compared to the same quarter last year. On average, sell-side analysts predict that Eli Lilly and Company will post 13.79 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 10th. Investors of record on Friday, November 15th will be given a dividend of $1.30 per share. The ex-dividend date is Friday, November 15th. This represents a $5.20 dividend on an annualized basis and a yield of 0.63%. Eli Lilly and Company’s payout ratio is presently 56.22%.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.